The global oligonucleotide synthesis market is expected to grow at a CAGR of 17.6% over the projection period, from USD 6.3 billion in 2021 to USD 14.1 billion in 2026. The rising usage of synthesised oligos in therapeutic applications, more government financing, and the expanding focus on customised medicine are all moving this sector forward.
The Effect of COVID-19 on the Global Oligonucleotide Synthesis Market
COVID-19 is a newly identified novel coronavirus that causes an infectious sickness. COVID-19, which was mostly unknown before the outbreak in Wuhan, China, in December 2019, has evolved from a regional issue to a global pandemic. COVID-19 has been officially declared a pandemic by the World Health Organization (WHO). A diverse group of established pharmaceutical and biopharmaceutical companies, as well as players in the oligonucleotide synthesis market, have stepped forward to support global research efforts by providing oligo products for the development of test kits, treatments, and vaccines that target the novel Coronavirus infection.
Access Full Report here : https://www.zionmarketresearch.com/report/oligonucleotide-synthesis-market
Market Trends in Oligonucleotide Synthesis
Driver: Government funding for synthetic biology and genomic initiatives should be increased.
Governments in a number of nations have recently made major investments in programmes connected to synthetic biology and genomics. These government investments have aided the development of new technology significantly. Oligonucleotides are an important aspect of these technologies, and increased financing and development in these domains will fuel market growth.
Restraint: Therapeutic oligos present a number of challenges.
Synthetic oligos have been increasingly important as therapeutic medications for treating diseases during the last decade. The characterisation of new targets following the discovery of the human genome, advances in antisense oligos, and the creation of double-stranded siRNA oligos are some of the key drivers of this expansion. Therapeutic oligos can also help with viral infections, respiratory disorders, cancer, and rare diseases such Duchenne Muscular Dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura.
Opportunity: Emerging economies’ key players
China, India, Singapore, and rising economies like Brazil all provide significant growth potential for the oligonucleotide synthesis market. This potential is mostly attributable to rising R&D spending by numerous corporations in Asia Pacific and Latin America’s emerging economies.
Challenge: oligonucleotide medication delivery to specified targets
In both experimental and clinical contexts, the use of gene therapy and antisense therapy to mediate tumour regression has been well proven. However, transferring knowledge into widespread clinical uses remains a challenge. The absence of delivery mechanisms that reliably deliver an effective dose of a therapeutic gene or antisense medication to the intended tumour site is one of the primary issues in cancer gene therapy and antisense therapy. The distribution of antisense drugs to distant tumours for therapeutic purposes is a difficult endeavour that necessitates the development of delivery vectors capable of overcoming numerous obstacles. Many researchers have used viral and nonviral vectors to deliver therapeutic genes or antisense compounds to tumour cells or tissues. Despite the optimistic outcomes of early gene therapy and antisense treatment-based clinical trials employing viral or non-viral vectors, finding a single approach that fits all of the parameters for perfect gene transfer and vector expression remains difficult.
The market for oligonucleotide synthesis is divided into the following segments and subsegments, according to the study:
Oligonucleotide synthesis Market, by Product
● Oligonucleotide-based drugs
● Synthesized oligonucleotides
Oligonucleotide synthesis Market, by Application
● Therapeutic applications
● Research applications
● Diagnostic applications
The oligonucleotide synthesis market is dominated by a few globally established players such as Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US). The prominent players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).
Read more at : https://www.zionmarketresearch.com/news/oligonucleotide-synthesis-market
• Danaher Corporation (US) established IDT China, an official corporate organisation, in 2020 to better serve its regional customer base, reach out to new customers, and make its whole array of industry-leading products more accessible.
• Danaher (US) bought General Electric Company’s (US) Life Sciences division’s Biopharma business in 2020. This subsidiary will be known as Cytiva and will operate independently inside Danaher’s Life Sciences business. Danaher’s position in the oligo synthesiser and reagents sector was improved by this acquisition.
• Primer-Probe Sets for SARS-CoV-2 were released by Microsynth AG (Switzerland) in 2020.
• LGC Limited (UK) and the Paraná Institute of Molecular Biology (IBMP) (Brazil) teamed in 2020 to create a novel molecular test for ZDC by supplying dependable, high-quality bespoke GMP oligonucleotides and molecular products (zika, dengue, and chikungunya).
About Us :
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.